NCT03357471 - Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 3, 2017

Primary Completion Date

July 2, 2018

Study Completion Date

July 2, 2018

Conditions

Moderate and Severe Active Rheumatoid ArthritisActive Psoriatic ArthritisActive Ankylosing SpondylitisModerately to Severely Active Crohn's Disease

Interventions

DRUG

e-Device

"* Active Substance: Certolizumab Pegol~* Pharmaceutical form: Solution for injection~* Route of administration: subcutaneous injection by e-Device"

Trial Locations (22)

11021

Ra0098 117, Great Neck

29572

Ra0098 113, Myrtle Beach

30501

Ra0098 127, Gainesville

33071

Ra0098 132, Coral Springs

34711

Ra0098 131, Clermont

37343

Ra0098 126, Hixson

50265

Ra0098 122, Clive

63110

Ra0098 105, St Louis

63128

Ra0098 104, St Louis

77058

Ra0098 106, Nassau Bay

78229

Ra0098 114, San Antonio

78404

Ra0098 128, Corpus Christi

78731

Ra0098 111, Austin

78745

Ra0098 123, Austin

78758

Ra0098 102, Austin

85037

Ra0098 135, Phoenix

85202

Ra0098 116, Mesa

85306

Ra0098 107, Mesa

85704

Ra0098 119, Tucson

91722

Ra0098 101, Covina

99352

Ra0098 133, Richland

07801

Ra0098 103, Dover

All Listed Sponsors

lead

UCB Biopharma S.P.R.L.

INDUSTRY